About Imunexus Therapeutics

Imunexus Therapeutics Ltd (Imunexus) is a biologics company with a unique approach to drug development that is centered around proprietary technology that facilitates rapid, cost-effective, lower risk, generation of therapeutics. Imunexus converts existing monospecific biologic drugs (with many of these being on-market off patent drugs) into bispecific versions that now have a additional therapeutic utilities. This strategy targets addressable markets with proven therapeutic targets, de-risking both development and commercialisation. Imunexus is applying its unique platform to develop bispecific drug candidates for the treatment of a number of cancer indications, autoimmune diseases, neuropathologies and other life-threatening illnesses.


Monoclonal Antibodies: Imunexus ‘Turbo Charges’ existing monoclonal antibodies by combining monoclonal antibodies with the Company’s proprietary imunexinsTM modules. Existing monoclonal antibodies include marketed antibodies, clinical stage antibodies, and advanced preclinical antibodies. The imunexinTM platform allows monospecific antibodies (i.e. they target to one therapeutic target) to be converted into bi- or trispecific antibodies (i.e. they now target two or three therapeutic targets). Once the antibodies are converted into multispecific versions with additional therapeutic properties, the potential clinical performance of the antibody is improved, hence “Turbo Charging” the existing antibody drug.

Enzyme Replacement Therapies: ImunexinTM modules are added to therapeutic enzymes to generate bispecific enzymes with additional therapeutic properties.   Adding imunexinsTM to the original enzyme can improve the enzymes' half-life (extending how long the enzyme remains in the blood stream) or by adding a targeting function that directs the enzyme to the site of disease.


Imunexus is currently focusing on three lead products that deal with serious diseases. One product is a bispecific antibody treatment for small cell lung cancer (IMX101). Small cell lung cancer (SCLC) is a severe disease with limited treatments (classified as an unmet medical need) and with a very poor prognosis. Imunexus is also developing bispecific enzyme treatments for a rare pediatric disease (IMX113) and for multiple sclerosis (IMX39).